SlideShare una empresa de Scribd logo
1 de 38
Survival Analysis and Cox
Regression for Cancer Trials
      Presented at PG Department of Statistics,
      Sardar Patel University January 29, 2013




                     Dr. Bhaswat S. Chakraborty
              Sr. VP & Chair, R&D Core Committee
            Cadila Pharmaceuticals Ltd., Ahmedabad


  1
Part 2: Cox Regression
    Analysis of Cancer CTs



2
Clinical Trials
   Organized scientific efforts to get direct answers from
    relevant patients on important scientific questions on
    (doses and regimens of) actions of drugs (or devices or
    other interventions).
   Questions are mainly about differences or null
   Modern trials (last 40 years or so) are large, multicentre,
    often international and co-operative endeavors
   Ideally, primary objectives are consistent with mechanism
    of action
   Results can be translated to practice
   Would stand the regulatory and scientific scrutiny
3
Cancer Trials (Phases I–IV)
       Highly complex trials involving cytotoxic drugs, moribund patients,
        time dependent and censored variables
       Require prolonged observation of each patient
       Expensive, long term and resource intensive trials
       Heterogeneous patients at various stages of the disease
       Prognostic factors of non-metastasized and metastasized diseases are
        different
       Adverse reactions are usually serious and frequently include death
       Ethical concerns are numerous and very serious
       Trial management is difficult and patient recruitment extremely
        challenging
       Number of stopped trials (by DSMB or FDA) is very high
       Data analysis and interpretation are very difficult by any standard
    5
6
    Source: WHO
7
India: 2010
       7137 of 122 429 study deaths were due to cancer, corresponding to 556 400 national
        cancer deaths in India in 2010.
       395 400 (71%) cancer deaths occurred in people aged 30—69 years (200 100 men
        and 195 300 women).
       At 30—69 years, the three most common fatal cancers were oral (including lip and
        pharynx, 45 800 [22·9%]), stomach (25 200 [12·6%]), and lung (including trachea
        and larynx, 22 900 [11·4%]) in men, and cervical (33 400 [17·1%]), stomach
        (27 500 [14·1%]), and breast (19 900 [10·2%]) in women.
       Tobacco-related cancers represented 42·0% (84 000) of male and 18·3% (35 700) of
        female cancer deaths and there were twice as many deaths from oral cancers as lung
        cancers.
       Age-standardized cancer mortality rates per 100 000 were similar in rural (men 95·6
        [99% CI 89·6—101·7] and women 96·6 [90·7—102·6]) and urban areas (men 102·4
        [92·7—112·1] and women 91·2 [81·9—100·5]), but varied greatly between the
        states.
       Cervical cancer was far less common in Muslim than in Hindu women (study deaths
        24, age-standardized mortality ratio 0·68 [0·64—0·71] vs 340, 1·06 [1·05—1·08]).
    8
10
Survival Analysis
 Survival analysis is studying the time between entry
  to a study and a subsequent event (such as death).
 Also called “time to event analysis”
 Survival analysis attempts to answer questions such
  as:
       which fraction of a population will survive past a certain
        time ?
       at what rate will they fail ?
       at what rate will they present the event ?
       How do particular factors benefit or affect the probability of
        survival ?

 11
What kind of time to event data?
   Survival Analysis typically focuses on time to event data.
   In the most general sense, it consists of techniques for
    positive-valued random variables, such as
       time to death
       time to onset (or relapse) of a disease
       length of stay in a hospital
       money paid by health insurance
       viral load measurements
   Kinds of survival studies include:
       clinical trials
       prospective cohort studies
       retrospective cohort studies
       retrospective correlative studies
12
Definition and Characteristics of Variables
   Survival time (t) random variables (RVs) are always non-
    negative, i.e., t ≥ 0.
   T can either be discrete (taking a finite set of values, e.g.
    a1, a2, …, an) or continuous [defined on (0,∞)].
   A random variable t is called a censored survival time RV
    if x = min(t, u), where u is a non-negative censoring
    variable.
   For a survival time RV, we need:
       (1) an unambiguous time origin (e.g. randomization to clinical
        trial)
       (2) a time scale (e.g. real time (days, months, years)
       (3) defnition of the event (e.g. death, relapse)
13
Event
                               Test
                                               Non-Event

Sample of Target   Randomize
  Population


                                                 Event
                               Control
                                                 Non-Event



                               Time to Event

  14
Illustration of Survival Data




15
Why Regression for Survival Data?
    Survival, in the form of hazard function, and one or more
     explanatory co-variables can be very interesting research
     investigation
    The relation with risk factors can be studied using group-
     specific Kaplan-Meier estimates, together with Logrank and/or
     Wilcoxon tests
    Investigating the relation with covariates, requires a
     regression-type model
    Relating the outcome to several factors and/or covariates
     simultaneously requires multiple regression, ANOVA, or
     ANCOVA models
    The most frequently used model is the Cox (proportional
     hazards) model
    16
Understanding the Effect of Co-variables




17
Cox Proportional Hazards Regression
   Most common Cox are linear-like models for the log
    hazard
       For example, a parametric regression model based on the
        exponential distribution:
           loge hi(t) = α + β1xi1 + β2xi2 + … + βkxik
   or, equivalently,
          hi(t) = exp (α + β1xi1 + β2xi2 + … + βkxik)

                 = eα x eβ1xi1 x eβ2xi2 x … x eβkxik
 Where
 i indexes subjects and

 xi1, xi2, …, xik are the values of the co-variates for the ith
 18
  subject
Cox Model contd..
    This is therefore a linear model for the log-hazard or a multiplicative
     model for the hazard itself
    The model is parametric because, once the regression parameters α,
     β1, … βk are specified, the hazard function hi(t) is fully characterized by
     the model
    The regression constant α represents a kind of baseline hazard, since
     loge hi(t) = α, or equivalently, hi(t) = eα, when all of the x’s are 0
    Other parametric hazard regression models are based on other
     distributions commonly used in modeling survival data, such as the
     Gompertz and Weibull distributions.
    Parametric hazard models can be estimated with standards softwares


    19
                                                                     Source: John Fox
Cox Regression is a Proportional Hazards
Model
    Consider two observations, h1(t): hazard for the experimental group and
     h0(t): hazard for the control group

                                  h1(t)/h0(t) = exp(β)
    exp (β) indicates how large (small) is the hazard in experimental group with
     the respect to the hazard in the reference group
    and it is constant, does not depend on time. Hence, it is called “proportional
     hazards” over time
    Other qualities:
      Usually provides better estimates of survival probabilities and
        cumulative hazard than those provided by the Kaplan-Meier function
        when assumptions are met
    The coefficients in a Cox regression relate to hazard
        a positive coefficient indicates a worse prognosis
        a negative coefficient indicates a protective effect of the variable with which it is
         associated
    20
Exploring Co-variables by Cox Regression




21                         Source: Yesilda Balavarca, Internet
Interpretation of Results
          h1 (t,X) = h0(t) exp (β1 gender + β2 treatment)
    Gender: 1 = male, 0 = female; treament: 1 = experimental,
     0 = control
     h1 (t,X) = h0(t) exp (−0.51 gender + 0.69 treatment) and
     exp(β1 ) = exp(−0.51 ) = 0.6 and exp(β2 ) = exp(0.69 ) = 2.0
    This means a reduction of hazards for males, i.e., males have
     larger probabilities of survival than females
    The experimental treatment increases hazard, i.e., patients
     receiving the new experimental treatment have lower survival
     probabilities than patients on the control (standard) treatment

    22
Checking Proportionality of Hazards
   Check to see if the estimated survival curves cross
       If they do, then this is evidence that the hazards are not
        proportional
   More formal test: e.g., scaled Schoenfeld Residuals show
    interactions between covariates and time
       Testing the time dependent covariates is equivalent to testing
        for a non-zero slope in a generalized linear regression of the
        scaled Schoenfeld residuals on functions of time
       A non-zero slope is an indication of a violation of the
        proportional hazard assumption.


23
Proportionality of Hazards: Schoenfeld
Residuals




24
Cox Regression is a Proportional Hazards
Model
    Cox regression (or proportional hazards regression) is method
     for investigating the effect of several variables upon the time a
     specified event takes to happen
    When an outcome is death this is known as Cox regression for
     survival analysis
    Assumptions:
        the effects of the predictor variables upon survival are constant over time
        are additive in one scale
    Usually provides better estimates of survival probabilities and
     cumulative hazard than those provided by the Kaplan-Meier
     function when assumptions are met
    The coefficients in a Cox regression relate to hazard
        a positive coefficient indicates a worse prognosis
        a negative coefficient indicates a protective effect of the variable with
         which it is associated
    25
Remember the Survival Data in
Part 1?



26
Organized Input Data
Group Surv Time Surv Censor Surv   Group Surv   Time Surv Censor Surv
         2        142          1            2         232           1
         1        143          1            2         232           1
         2        157          1            2         232           1
         2        163          1            2         233           1
         1        165          1            2         233           1
         1        188          1            2         233           1
         1        188          1            2         233           1
                                            1         235           1
         1        190          1            2         239           1
         1        192          1            2         240           1
         2        198          1            1         244           0
         2        204          0            1         246           1
         2        205          1            2         261           1
         1        206          1            1         265           1
         1        208          1            2         280           1
         1        212          1            2         280           1
         1        216          0            2         295           1
         1        216          1            2         295           1
         1        220          1            1         303           1
         1        227          1            2         323           1
         1        230          1            2         344           0
 27
Hazard Rate Plot




28
Log Hazard Plot




29
Cox Hazard Analysis
                         95% Conf.                               Hazard =
          Coefficient       (±)    Std.Error           P        Exp(Coef.)


 Group
 Surv     -0.5861172 0.6726008 0.343165             0.0876        0.55648


The significance test for the coefficient b1 tests the null hypothesis that it
equals zero and thus that its exponent equals one

The confidence interval for b1 is therefore the confidence interval for the
relative death rate or hazard ratio


What is your conclusion of this analysis?
30
And the Case Study Data in
Part 1?



31
Case Study: Results
   Cox proportional hazards:
       Factors associated with increased mortality risk were male
        sex, poor KPS (< 80), presence of liver metastases, high
        serum lactate dehydrogenase, and low serum albumin.
       Adjusted for these variables, there was no statistically
        significant difference in survival rates between patients
        treated with gemcitabine and marimastat 25 mg, but patients
        receiving either marimastat 10 or 5 mg were found to have a
        significantly worse survival rate than those receiving
        gemcitabine



32
33
Bad or Wrong Methods of Analysis
    Comparison of life tables at one point in time ignoring their structure
     elsewhere (except very rapid processes)
    If a few patients are at risk for more than a certain time but do not die, this
     should not be taken as evidence of cure. Look at all the data of all the
     patients
    Median survival times are not very reliable unless the death rate around that
     median is very high
    A simple count of number of death in each group is inefficient as it ignores
     the rate of death
    The best estimate of the probability of survival for a certain time (say 5
     years), is given by the life table value at that time. Other simplistic
     calculations may be misleading
    Randomized controls are always better than historical controls



    34
Bad or Wrong Methods of Analysis contd.
    Estimation of survival is best done from randomization time. If it is done
     from the time of 1st treatment it can be misleading (as initiating time for two
     treatments can be different)
    Superficial comparison of the slopes of survival graphs as it biases the
     proportion surviving at each given time
    Declaring ITT is better than per protocol analysis or the reverse
      Check all the data carefully especially the P values associated with either
        type of analysis
    When you get an overall non-significant treatment effect, do not insist that
     a sub-stratum can still benefit from the treatment even if that stratum
     analysis is significant
    Realistically not checking the actual number of survivors on the last day of
     the study (follow up)
    Be sure of your reason to use and report one-sided vs. two-sided t-tests

    35
Overall Conclusions
    Survival time is measured for each patient from his/her date of
     randomization
    The life table is a table or graph estimating the proportion of
     surviving patients at different times after randomization
    The Log Rank test is a comparison of observed and expected
     death in each experimental group
        P value of Log Rank can be estimated by a chi square (χ2 ) test.
    A patients are divided into strata (prospectively or
     retrospectively), K-M life tables or Log Rank can be used to
     compare prognosis in each stratum, for testing heterogeneity,
     etc.
    Usually Cox regression yields slightly better analysis of cancer
     trial data provided assumptions are met
    36
Notes 1




37
Notes 2




38
End of Part 2

       Your ?s


39
Thank You Very Much




40

Más contenido relacionado

La actualidad más candente

Survival Analysis Lecture.ppt
Survival Analysis Lecture.pptSurvival Analysis Lecture.ppt
Survival Analysis Lecture.ppt
habtamu biazin
 

La actualidad más candente (20)

Survival analysis
Survival analysis  Survival analysis
Survival analysis
 
Sample size calculation
Sample size calculationSample size calculation
Sample size calculation
 
Survival Analysis Using SPSS
Survival Analysis Using SPSSSurvival Analysis Using SPSS
Survival Analysis Using SPSS
 
Survival Data Analysis for Sekolah Tinggi Ilmu Statistik Jakarta
Survival Data Analysis for Sekolah Tinggi Ilmu Statistik JakartaSurvival Data Analysis for Sekolah Tinggi Ilmu Statistik Jakarta
Survival Data Analysis for Sekolah Tinggi Ilmu Statistik Jakarta
 
SURVIVAL ANALYSIS.ppt
SURVIVAL ANALYSIS.pptSURVIVAL ANALYSIS.ppt
SURVIVAL ANALYSIS.ppt
 
演講-Meta analysis in medical research-張偉豪
演講-Meta analysis in medical research-張偉豪演講-Meta analysis in medical research-張偉豪
演講-Meta analysis in medical research-張偉豪
 
Metaanalysis copy
Metaanalysis    copyMetaanalysis    copy
Metaanalysis copy
 
Cohort studies
Cohort studiesCohort studies
Cohort studies
 
Sample size calculations
Sample size calculationsSample size calculations
Sample size calculations
 
Sample size estimation
Sample size estimationSample size estimation
Sample size estimation
 
Sample Size Determination
Sample Size DeterminationSample Size Determination
Sample Size Determination
 
Odds ratio and confidence interval
Odds ratio and confidence intervalOdds ratio and confidence interval
Odds ratio and confidence interval
 
SURVIVAL ANALYSIS 1.pptx
SURVIVAL ANALYSIS 1.pptxSURVIVAL ANALYSIS 1.pptx
SURVIVAL ANALYSIS 1.pptx
 
Error, bias and confounding
Error, bias and confoundingError, bias and confounding
Error, bias and confounding
 
ODDS RATIO AND RELATIVE RISK EVALUATION
ODDS RATIO AND RELATIVE RISK EVALUATIONODDS RATIO AND RELATIVE RISK EVALUATION
ODDS RATIO AND RELATIVE RISK EVALUATION
 
P value, Power, Type 1 and 2 errors
P value, Power, Type 1 and 2 errorsP value, Power, Type 1 and 2 errors
P value, Power, Type 1 and 2 errors
 
1. Introduction to Survival analysis
1. Introduction to Survival analysis1. Introduction to Survival analysis
1. Introduction to Survival analysis
 
Sample size calculation in medical research
Sample size calculation in medical researchSample size calculation in medical research
Sample size calculation in medical research
 
Survival Analysis Lecture.ppt
Survival Analysis Lecture.pptSurvival Analysis Lecture.ppt
Survival Analysis Lecture.ppt
 
Odds ratios (Basic concepts)
Odds ratios (Basic concepts)Odds ratios (Basic concepts)
Odds ratios (Basic concepts)
 

Destacado

Yisen Lin's Term 2 Presentation
Yisen Lin's Term 2 PresentationYisen Lin's Term 2 Presentation
Yisen Lin's Term 2 Presentation
Yisen Lin
 
Systematic Review Of Observational Studies By Yusuf Abdu Misau
Systematic Review Of Observational Studies By Yusuf Abdu MisauSystematic Review Of Observational Studies By Yusuf Abdu Misau
Systematic Review Of Observational Studies By Yusuf Abdu Misau
Yusuf Misau
 
Classification and Regression Tree Analysis in Biomedical Research
Classification and Regression Tree Analysis in Biomedical Research Classification and Regression Tree Analysis in Biomedical Research
Classification and Regression Tree Analysis in Biomedical Research
Salford Systems
 
Kaplan meier survival curves and the log-rank test
Kaplan meier survival curves and the log-rank testKaplan meier survival curves and the log-rank test
Kaplan meier survival curves and the log-rank test
zhe1
 

Destacado (20)

Use Proportional Hazards Regression Method To Analyze The Survival of Patient...
Use Proportional Hazards Regression Method To Analyze The Survival of Patient...Use Proportional Hazards Regression Method To Analyze The Survival of Patient...
Use Proportional Hazards Regression Method To Analyze The Survival of Patient...
 
Wesat2203
Wesat2203Wesat2203
Wesat2203
 
Rodriguez_NRMC_Presentation
Rodriguez_NRMC_PresentationRodriguez_NRMC_Presentation
Rodriguez_NRMC_Presentation
 
Adult HIV: Management of patients on antiretroviral treatment
Adult HIV: Management of patients on antiretroviral treatmentAdult HIV: Management of patients on antiretroviral treatment
Adult HIV: Management of patients on antiretroviral treatment
 
Yisen Lin's Term 2 Presentation
Yisen Lin's Term 2 PresentationYisen Lin's Term 2 Presentation
Yisen Lin's Term 2 Presentation
 
Evaluating Racial Disparities in Survival after AIDS Diagnosis using Standard...
Evaluating Racial Disparities in Survival after AIDS Diagnosis using Standard...Evaluating Racial Disparities in Survival after AIDS Diagnosis using Standard...
Evaluating Racial Disparities in Survival after AIDS Diagnosis using Standard...
 
Survival Analysis Project
Survival Analysis Project Survival Analysis Project
Survival Analysis Project
 
Impact of censored data on reliability analysis
Impact of censored data on reliability analysisImpact of censored data on reliability analysis
Impact of censored data on reliability analysis
 
Systematic Review Of Observational Studies By Yusuf Abdu Misau
Systematic Review Of Observational Studies By Yusuf Abdu MisauSystematic Review Of Observational Studies By Yusuf Abdu Misau
Systematic Review Of Observational Studies By Yusuf Abdu Misau
 
Classification and Regression Tree Analysis in Biomedical Research
Classification and Regression Tree Analysis in Biomedical Research Classification and Regression Tree Analysis in Biomedical Research
Classification and Regression Tree Analysis in Biomedical Research
 
Antiretroviral Treatment of Adult with HIV Infection The guidelines of Inter...
Antiretroviral Treatment of Adult with HIV Infection The guidelines of Inter...Antiretroviral Treatment of Adult with HIV Infection The guidelines of Inter...
Antiretroviral Treatment of Adult with HIV Infection The guidelines of Inter...
 
A gentle introduction to survival analysis
A gentle introduction to survival analysisA gentle introduction to survival analysis
A gentle introduction to survival analysis
 
Hiv&aids in kenya
Hiv&aids in kenyaHiv&aids in kenya
Hiv&aids in kenya
 
Kaplan meier survival curves and the log-rank test
Kaplan meier survival curves and the log-rank testKaplan meier survival curves and the log-rank test
Kaplan meier survival curves and the log-rank test
 
Kshivets O. Esophageal Cancer Surgery
Kshivets O. Esophageal Cancer SurgeryKshivets O. Esophageal Cancer Surgery
Kshivets O. Esophageal Cancer Surgery
 
HIV epidemiology and pathogenesis
HIV epidemiology and pathogenesis HIV epidemiology and pathogenesis
HIV epidemiology and pathogenesis
 
Student's T-test, Paired T-Test, ANOVA & Proportionate Test
Student's T-test, Paired T-Test, ANOVA & Proportionate TestStudent's T-test, Paired T-Test, ANOVA & Proportionate Test
Student's T-test, Paired T-Test, ANOVA & Proportionate Test
 
Analysis of variance (ANOVA)
Analysis of variance (ANOVA)Analysis of variance (ANOVA)
Analysis of variance (ANOVA)
 
Reporting a one-way anova
Reporting a one-way anovaReporting a one-way anova
Reporting a one-way anova
 
HIV AIDS
HIV AIDSHIV AIDS
HIV AIDS
 

Similar a Part 2 Cox Regression

Frequency Measures Used in EpidemiologyIntroductionIn e.docx
 Frequency Measures Used in EpidemiologyIntroductionIn e.docx Frequency Measures Used in EpidemiologyIntroductionIn e.docx
Frequency Measures Used in EpidemiologyIntroductionIn e.docx
MARRY7
 
Logistic Loglogistic With Long Term Survivors For Split Population Model
Logistic Loglogistic With Long Term Survivors For Split Population ModelLogistic Loglogistic With Long Term Survivors For Split Population Model
Logistic Loglogistic With Long Term Survivors For Split Population Model
Waqas Tariq
 
2019 10 11 Originality ReportiginalityReportultraattem.docx
2019 10 11 Originality ReportiginalityReportultraattem.docx2019 10 11 Originality ReportiginalityReportultraattem.docx
2019 10 11 Originality ReportiginalityReportultraattem.docx
domenicacullison
 
Pai_Lecture3_Measures of Disease Freq.pdf
Pai_Lecture3_Measures of Disease Freq.pdfPai_Lecture3_Measures of Disease Freq.pdf
Pai_Lecture3_Measures of Disease Freq.pdf
kihembopamelah
 
Categorical-data-afghvvghgfhg.analysis.ppt
Categorical-data-afghvvghgfhg.analysis.pptCategorical-data-afghvvghgfhg.analysis.ppt
Categorical-data-afghvvghgfhg.analysis.ppt
qkmaiu
 

Similar a Part 2 Cox Regression (20)

Survival analysis
Survival analysisSurvival analysis
Survival analysis
 
Cox model
Cox modelCox model
Cox model
 
lecture1 on survival analysis HRP 262 class
lecture1 on survival analysis HRP 262 classlecture1 on survival analysis HRP 262 class
lecture1 on survival analysis HRP 262 class
 
Art01
Art01Art01
Art01
 
Nice sugar study
Nice sugar studyNice sugar study
Nice sugar study
 
Probability Models for Estimating Haplotype Frequencies and Bayesian Survival...
Probability Models for Estimating Haplotype Frequencies and Bayesian Survival...Probability Models for Estimating Haplotype Frequencies and Bayesian Survival...
Probability Models for Estimating Haplotype Frequencies and Bayesian Survival...
 
Common statistical pitfalls & errors in biomedical research (a top-5 list)
Common statistical pitfalls & errors in biomedical research (a top-5 list)Common statistical pitfalls & errors in biomedical research (a top-5 list)
Common statistical pitfalls & errors in biomedical research (a top-5 list)
 
TestSurvRec manual
TestSurvRec manualTestSurvRec manual
TestSurvRec manual
 
Restricted Mean Survival Analysis
Restricted Mean Survival AnalysisRestricted Mean Survival Analysis
Restricted Mean Survival Analysis
 
Frequency Measures Used in EpidemiologyIntroductionIn e.docx
 Frequency Measures Used in EpidemiologyIntroductionIn e.docx Frequency Measures Used in EpidemiologyIntroductionIn e.docx
Frequency Measures Used in EpidemiologyIntroductionIn e.docx
 
Logistic Loglogistic With Long Term Survivors For Split Population Model
Logistic Loglogistic With Long Term Survivors For Split Population ModelLogistic Loglogistic With Long Term Survivors For Split Population Model
Logistic Loglogistic With Long Term Survivors For Split Population Model
 
2019 10 11 Originality ReportiginalityReportultraattem.docx
2019 10 11 Originality ReportiginalityReportultraattem.docx2019 10 11 Originality ReportiginalityReportultraattem.docx
2019 10 11 Originality ReportiginalityReportultraattem.docx
 
Surveillance of healthcare-associated infections: understanding and utilizing...
Surveillance of healthcare-associated infections: understanding and utilizing...Surveillance of healthcare-associated infections: understanding and utilizing...
Surveillance of healthcare-associated infections: understanding and utilizing...
 
A SEIR MODEL FOR CONTROL OF INFECTIOUS DISEASES
A SEIR MODEL FOR CONTROL OF INFECTIOUS DISEASESA SEIR MODEL FOR CONTROL OF INFECTIOUS DISEASES
A SEIR MODEL FOR CONTROL OF INFECTIOUS DISEASES
 
Pai_Lecture3_Measures of Disease Freq.pdf
Pai_Lecture3_Measures of Disease Freq.pdfPai_Lecture3_Measures of Disease Freq.pdf
Pai_Lecture3_Measures of Disease Freq.pdf
 
HLTH 104 Chapter 02
HLTH 104 Chapter 02HLTH 104 Chapter 02
HLTH 104 Chapter 02
 
Seminar-2015
Seminar-2015Seminar-2015
Seminar-2015
 
Categorical-data-afghvvghgfhg.analysis.ppt
Categorical-data-afghvvghgfhg.analysis.pptCategorical-data-afghvvghgfhg.analysis.ppt
Categorical-data-afghvvghgfhg.analysis.ppt
 
Non-Parametric Survival Models
Non-Parametric Survival ModelsNon-Parametric Survival Models
Non-Parametric Survival Models
 
Fundamentals and Study Design of Epidemiology
Fundamentals and Study Design of EpidemiologyFundamentals and Study Design of Epidemiology
Fundamentals and Study Design of Epidemiology
 

Más de Bhaswat Chakraborty

Más de Bhaswat Chakraborty (20)

Root cause Analysis (RCA) & Corrective and Preventive action (CAPA) in MRCT d...
Root cause Analysis (RCA) & Corrective and Preventive action (CAPA) in MRCT d...Root cause Analysis (RCA) & Corrective and Preventive action (CAPA) in MRCT d...
Root cause Analysis (RCA) & Corrective and Preventive action (CAPA) in MRCT d...
 
Statistical outliers in BE Studies DIA 12 april 2019
Statistical outliers in BE Studies DIA 12 april 2019Statistical outliers in BE Studies DIA 12 april 2019
Statistical outliers in BE Studies DIA 12 april 2019
 
Respiratory studies right approach in designs dia 11 april 2019 r
Respiratory studies right approach  in designs dia 11 april 2019 rRespiratory studies right approach  in designs dia 11 april 2019 r
Respiratory studies right approach in designs dia 11 april 2019 r
 
Simplifying study designs and statistical models for new dose & dosage forms ...
Simplifying study designs and statistical models for new dose & dosage forms ...Simplifying study designs and statistical models for new dose & dosage forms ...
Simplifying study designs and statistical models for new dose & dosage forms ...
 
Equivalence approches for complex generics DIA 11 april 2019
Equivalence approches for complex generics DIA 11 april 2019 Equivalence approches for complex generics DIA 11 april 2019
Equivalence approches for complex generics DIA 11 april 2019
 
Clinical Trial Requirements Medical Devices 27 dec2018
Clinical Trial Requirements Medical Devices 27 dec2018Clinical Trial Requirements Medical Devices 27 dec2018
Clinical Trial Requirements Medical Devices 27 dec2018
 
Writing scientific papers FINALDec 2018
Writing scientific papers FINALDec 2018Writing scientific papers FINALDec 2018
Writing scientific papers FINALDec 2018
 
Multidisc review of NDAs and BLAs nipicon 2018 Dr. Chakraborty
Multidisc review of NDAs and BLAs nipicon 2018 Dr. ChakrabortyMultidisc review of NDAs and BLAs nipicon 2018 Dr. Chakraborty
Multidisc review of NDAs and BLAs nipicon 2018 Dr. Chakraborty
 
Teaching by stories, anecdotes and historical facts sept 25 2018
Teaching by stories, anecdotes and historical facts sept 25 2018Teaching by stories, anecdotes and historical facts sept 25 2018
Teaching by stories, anecdotes and historical facts sept 25 2018
 
Orientation and Adaptation for Post-Graduate Pharmacy Programs
Orientation and Adaptation for Post-Graduate Pharmacy ProgramsOrientation and Adaptation for Post-Graduate Pharmacy Programs
Orientation and Adaptation for Post-Graduate Pharmacy Programs
 
Plagiarism and Techniques to Avoid Plagiarism
Plagiarism and Techniques to Avoid PlagiarismPlagiarism and Techniques to Avoid Plagiarism
Plagiarism and Techniques to Avoid Plagiarism
 
Best Practices to Risk Based Data Integrity at Data Integrity Conference, Lon...
Best Practices to Risk Based Data Integrity at Data Integrity Conference, Lon...Best Practices to Risk Based Data Integrity at Data Integrity Conference, Lon...
Best Practices to Risk Based Data Integrity at Data Integrity Conference, Lon...
 
Ethics in Pharmacy
Ethics in Pharmacy Ethics in Pharmacy
Ethics in Pharmacy
 
Pharmacists in Drug Discovery & Development
Pharmacists in Drug Discovery & Development Pharmacists in Drug Discovery & Development
Pharmacists in Drug Discovery & Development
 
Clinical Development of Biosimilars
Clinical Development of Biosimilars Clinical Development of Biosimilars
Clinical Development of Biosimilars
 
Challenges in Phase III Cancer Clinical Trials
Challenges in Phase III Cancer Clinical Trials Challenges in Phase III Cancer Clinical Trials
Challenges in Phase III Cancer Clinical Trials
 
Bioequivalence of Highly Variable Drug Products
Bioequivalence of Highly Variable Drug ProductsBioequivalence of Highly Variable Drug Products
Bioequivalence of Highly Variable Drug Products
 
Bioequivalence of Highly Variable Drug Products
Bioequivalence of Highly Variable Drug ProductsBioequivalence of Highly Variable Drug Products
Bioequivalence of Highly Variable Drug Products
 
Protein binding of drugs and screening of drugs by physicochemical properties
Protein binding of drugs  and screening of drugs by physicochemical propertiesProtein binding of drugs  and screening of drugs by physicochemical properties
Protein binding of drugs and screening of drugs by physicochemical properties
 
Developing Protocols & Procedures for CT Data Integrity
Developing Protocols & Procedures for CT Data Integrity Developing Protocols & Procedures for CT Data Integrity
Developing Protocols & Procedures for CT Data Integrity
 

Último

💚Call Girls In Amritsar 💯Anvi 📲🔝8725944379🔝Amritsar Call Girl No💰Advance Cash...
💚Call Girls In Amritsar 💯Anvi 📲🔝8725944379🔝Amritsar Call Girl No💰Advance Cash...💚Call Girls In Amritsar 💯Anvi 📲🔝8725944379🔝Amritsar Call Girl No💰Advance Cash...
💚Call Girls In Amritsar 💯Anvi 📲🔝8725944379🔝Amritsar Call Girl No💰Advance Cash...
Sheetaleventcompany
 
Call Girl in Indore 8827247818 {LowPrice} ❤️ (ahana) Indore Call Girls * UPA...
Call Girl in Indore 8827247818 {LowPrice} ❤️ (ahana) Indore Call Girls  * UPA...Call Girl in Indore 8827247818 {LowPrice} ❤️ (ahana) Indore Call Girls  * UPA...
Call Girl in Indore 8827247818 {LowPrice} ❤️ (ahana) Indore Call Girls * UPA...
mahaiklolahd
 
Call Girl In Pune 👉 Just CALL ME: 9352988975 💋 Call Out Call Both With High p...
Call Girl In Pune 👉 Just CALL ME: 9352988975 💋 Call Out Call Both With High p...Call Girl In Pune 👉 Just CALL ME: 9352988975 💋 Call Out Call Both With High p...
Call Girl In Pune 👉 Just CALL ME: 9352988975 💋 Call Out Call Both With High p...
chetankumar9855
 
🌹Attapur⬅️ Vip Call Girls Hyderabad 📱9352852248 Book Well Trand Call Girls In...
🌹Attapur⬅️ Vip Call Girls Hyderabad 📱9352852248 Book Well Trand Call Girls In...🌹Attapur⬅️ Vip Call Girls Hyderabad 📱9352852248 Book Well Trand Call Girls In...
🌹Attapur⬅️ Vip Call Girls Hyderabad 📱9352852248 Book Well Trand Call Girls In...
Call Girls In Delhi Whatsup 9873940964 Enjoy Unlimited Pleasure
 

Último (20)

💚Call Girls In Amritsar 💯Anvi 📲🔝8725944379🔝Amritsar Call Girl No💰Advance Cash...
💚Call Girls In Amritsar 💯Anvi 📲🔝8725944379🔝Amritsar Call Girl No💰Advance Cash...💚Call Girls In Amritsar 💯Anvi 📲🔝8725944379🔝Amritsar Call Girl No💰Advance Cash...
💚Call Girls In Amritsar 💯Anvi 📲🔝8725944379🔝Amritsar Call Girl No💰Advance Cash...
 
Call Girls Rishikesh Just Call 8250077686 Top Class Call Girl Service Available
Call Girls Rishikesh Just Call 8250077686 Top Class Call Girl Service AvailableCall Girls Rishikesh Just Call 8250077686 Top Class Call Girl Service Available
Call Girls Rishikesh Just Call 8250077686 Top Class Call Girl Service Available
 
Jogeshwari ! Call Girls Service Mumbai - 450+ Call Girl Cash Payment 90042684...
Jogeshwari ! Call Girls Service Mumbai - 450+ Call Girl Cash Payment 90042684...Jogeshwari ! Call Girls Service Mumbai - 450+ Call Girl Cash Payment 90042684...
Jogeshwari ! Call Girls Service Mumbai - 450+ Call Girl Cash Payment 90042684...
 
Call Girls Mysore Just Call 8250077686 Top Class Call Girl Service Available
Call Girls Mysore Just Call 8250077686 Top Class Call Girl Service AvailableCall Girls Mysore Just Call 8250077686 Top Class Call Girl Service Available
Call Girls Mysore Just Call 8250077686 Top Class Call Girl Service Available
 
Call Girl in Indore 8827247818 {LowPrice} ❤️ (ahana) Indore Call Girls * UPA...
Call Girl in Indore 8827247818 {LowPrice} ❤️ (ahana) Indore Call Girls  * UPA...Call Girl in Indore 8827247818 {LowPrice} ❤️ (ahana) Indore Call Girls  * UPA...
Call Girl in Indore 8827247818 {LowPrice} ❤️ (ahana) Indore Call Girls * UPA...
 
Andheri East ^ (Genuine) Escort Service Mumbai ₹7.5k Pick Up & Drop With Cash...
Andheri East ^ (Genuine) Escort Service Mumbai ₹7.5k Pick Up & Drop With Cash...Andheri East ^ (Genuine) Escort Service Mumbai ₹7.5k Pick Up & Drop With Cash...
Andheri East ^ (Genuine) Escort Service Mumbai ₹7.5k Pick Up & Drop With Cash...
 
Call Girl In Pune 👉 Just CALL ME: 9352988975 💋 Call Out Call Both With High p...
Call Girl In Pune 👉 Just CALL ME: 9352988975 💋 Call Out Call Both With High p...Call Girl In Pune 👉 Just CALL ME: 9352988975 💋 Call Out Call Both With High p...
Call Girl In Pune 👉 Just CALL ME: 9352988975 💋 Call Out Call Both With High p...
 
💕SONAM KUMAR💕Premium Call Girls Jaipur ↘️9257276172 ↙️One Night Stand With Lo...
💕SONAM KUMAR💕Premium Call Girls Jaipur ↘️9257276172 ↙️One Night Stand With Lo...💕SONAM KUMAR💕Premium Call Girls Jaipur ↘️9257276172 ↙️One Night Stand With Lo...
💕SONAM KUMAR💕Premium Call Girls Jaipur ↘️9257276172 ↙️One Night Stand With Lo...
 
Russian Call Girls Service Jaipur {8445551418} ❤️PALLAVI VIP Jaipur Call Gir...
Russian Call Girls Service  Jaipur {8445551418} ❤️PALLAVI VIP Jaipur Call Gir...Russian Call Girls Service  Jaipur {8445551418} ❤️PALLAVI VIP Jaipur Call Gir...
Russian Call Girls Service Jaipur {8445551418} ❤️PALLAVI VIP Jaipur Call Gir...
 
Andheri East ) Call Girls in Mumbai Phone No 9004268417 Elite Escort Service ...
Andheri East ) Call Girls in Mumbai Phone No 9004268417 Elite Escort Service ...Andheri East ) Call Girls in Mumbai Phone No 9004268417 Elite Escort Service ...
Andheri East ) Call Girls in Mumbai Phone No 9004268417 Elite Escort Service ...
 
Call Girls Ahmedabad Just Call 9630942363 Top Class Call Girl Service Available
Call Girls Ahmedabad Just Call 9630942363 Top Class Call Girl Service AvailableCall Girls Ahmedabad Just Call 9630942363 Top Class Call Girl Service Available
Call Girls Ahmedabad Just Call 9630942363 Top Class Call Girl Service Available
 
Call Girls Kolkata Kalikapur 💯Call Us 🔝 8005736733 🔝 💃 Top Class Call Girl Se...
Call Girls Kolkata Kalikapur 💯Call Us 🔝 8005736733 🔝 💃 Top Class Call Girl Se...Call Girls Kolkata Kalikapur 💯Call Us 🔝 8005736733 🔝 💃 Top Class Call Girl Se...
Call Girls Kolkata Kalikapur 💯Call Us 🔝 8005736733 🔝 💃 Top Class Call Girl Se...
 
Independent Call Girls In Jaipur { 8445551418 } ✔ ANIKA MEHTA ✔ Get High Prof...
Independent Call Girls In Jaipur { 8445551418 } ✔ ANIKA MEHTA ✔ Get High Prof...Independent Call Girls In Jaipur { 8445551418 } ✔ ANIKA MEHTA ✔ Get High Prof...
Independent Call Girls In Jaipur { 8445551418 } ✔ ANIKA MEHTA ✔ Get High Prof...
 
Call Girls in Delhi Triveni Complex Escort Service(🔝))/WhatsApp 97111⇛47426
Call Girls in Delhi Triveni Complex Escort Service(🔝))/WhatsApp 97111⇛47426Call Girls in Delhi Triveni Complex Escort Service(🔝))/WhatsApp 97111⇛47426
Call Girls in Delhi Triveni Complex Escort Service(🔝))/WhatsApp 97111⇛47426
 
🌹Attapur⬅️ Vip Call Girls Hyderabad 📱9352852248 Book Well Trand Call Girls In...
🌹Attapur⬅️ Vip Call Girls Hyderabad 📱9352852248 Book Well Trand Call Girls In...🌹Attapur⬅️ Vip Call Girls Hyderabad 📱9352852248 Book Well Trand Call Girls In...
🌹Attapur⬅️ Vip Call Girls Hyderabad 📱9352852248 Book Well Trand Call Girls In...
 
Call Girls Amritsar Just Call 8250077686 Top Class Call Girl Service Available
Call Girls Amritsar Just Call 8250077686 Top Class Call Girl Service AvailableCall Girls Amritsar Just Call 8250077686 Top Class Call Girl Service Available
Call Girls Amritsar Just Call 8250077686 Top Class Call Girl Service Available
 
9630942363 Genuine Call Girls In Ahmedabad Gujarat Call Girls Service
9630942363 Genuine Call Girls In Ahmedabad Gujarat Call Girls Service9630942363 Genuine Call Girls In Ahmedabad Gujarat Call Girls Service
9630942363 Genuine Call Girls In Ahmedabad Gujarat Call Girls Service
 
Call Girls Service Jaipur {9521753030 } ❤️VVIP BHAWNA Call Girl in Jaipur Raj...
Call Girls Service Jaipur {9521753030 } ❤️VVIP BHAWNA Call Girl in Jaipur Raj...Call Girls Service Jaipur {9521753030 } ❤️VVIP BHAWNA Call Girl in Jaipur Raj...
Call Girls Service Jaipur {9521753030 } ❤️VVIP BHAWNA Call Girl in Jaipur Raj...
 
8980367676 Call Girls In Ahmedabad Escort Service Available 24×7 In Ahmedabad
8980367676 Call Girls In Ahmedabad Escort Service Available 24×7 In Ahmedabad8980367676 Call Girls In Ahmedabad Escort Service Available 24×7 In Ahmedabad
8980367676 Call Girls In Ahmedabad Escort Service Available 24×7 In Ahmedabad
 
Top Rated Call Girls Kerala ☎ 8250092165👄 Delivery in 20 Mins Near Me
Top Rated Call Girls Kerala ☎ 8250092165👄 Delivery in 20 Mins Near MeTop Rated Call Girls Kerala ☎ 8250092165👄 Delivery in 20 Mins Near Me
Top Rated Call Girls Kerala ☎ 8250092165👄 Delivery in 20 Mins Near Me
 

Part 2 Cox Regression

  • 1. Survival Analysis and Cox Regression for Cancer Trials Presented at PG Department of Statistics, Sardar Patel University January 29, 2013 Dr. Bhaswat S. Chakraborty Sr. VP & Chair, R&D Core Committee Cadila Pharmaceuticals Ltd., Ahmedabad 1
  • 2. Part 2: Cox Regression Analysis of Cancer CTs 2
  • 3. Clinical Trials  Organized scientific efforts to get direct answers from relevant patients on important scientific questions on (doses and regimens of) actions of drugs (or devices or other interventions).  Questions are mainly about differences or null  Modern trials (last 40 years or so) are large, multicentre, often international and co-operative endeavors  Ideally, primary objectives are consistent with mechanism of action  Results can be translated to practice  Would stand the regulatory and scientific scrutiny 3
  • 4. Cancer Trials (Phases I–IV)  Highly complex trials involving cytotoxic drugs, moribund patients, time dependent and censored variables  Require prolonged observation of each patient  Expensive, long term and resource intensive trials  Heterogeneous patients at various stages of the disease  Prognostic factors of non-metastasized and metastasized diseases are different  Adverse reactions are usually serious and frequently include death  Ethical concerns are numerous and very serious  Trial management is difficult and patient recruitment extremely challenging  Number of stopped trials (by DSMB or FDA) is very high  Data analysis and interpretation are very difficult by any standard 5
  • 5. 6 Source: WHO
  • 6. 7
  • 7. India: 2010  7137 of 122 429 study deaths were due to cancer, corresponding to 556 400 national cancer deaths in India in 2010.  395 400 (71%) cancer deaths occurred in people aged 30—69 years (200 100 men and 195 300 women).  At 30—69 years, the three most common fatal cancers were oral (including lip and pharynx, 45 800 [22·9%]), stomach (25 200 [12·6%]), and lung (including trachea and larynx, 22 900 [11·4%]) in men, and cervical (33 400 [17·1%]), stomach (27 500 [14·1%]), and breast (19 900 [10·2%]) in women.  Tobacco-related cancers represented 42·0% (84 000) of male and 18·3% (35 700) of female cancer deaths and there were twice as many deaths from oral cancers as lung cancers.  Age-standardized cancer mortality rates per 100 000 were similar in rural (men 95·6 [99% CI 89·6—101·7] and women 96·6 [90·7—102·6]) and urban areas (men 102·4 [92·7—112·1] and women 91·2 [81·9—100·5]), but varied greatly between the states.  Cervical cancer was far less common in Muslim than in Hindu women (study deaths 24, age-standardized mortality ratio 0·68 [0·64—0·71] vs 340, 1·06 [1·05—1·08]). 8
  • 8. 10
  • 9. Survival Analysis  Survival analysis is studying the time between entry to a study and a subsequent event (such as death).  Also called “time to event analysis”  Survival analysis attempts to answer questions such as:  which fraction of a population will survive past a certain time ?  at what rate will they fail ?  at what rate will they present the event ?  How do particular factors benefit or affect the probability of survival ? 11
  • 10. What kind of time to event data?  Survival Analysis typically focuses on time to event data.  In the most general sense, it consists of techniques for positive-valued random variables, such as  time to death  time to onset (or relapse) of a disease  length of stay in a hospital  money paid by health insurance  viral load measurements  Kinds of survival studies include:  clinical trials  prospective cohort studies  retrospective cohort studies  retrospective correlative studies 12
  • 11. Definition and Characteristics of Variables  Survival time (t) random variables (RVs) are always non- negative, i.e., t ≥ 0.  T can either be discrete (taking a finite set of values, e.g. a1, a2, …, an) or continuous [defined on (0,∞)].  A random variable t is called a censored survival time RV if x = min(t, u), where u is a non-negative censoring variable.  For a survival time RV, we need:  (1) an unambiguous time origin (e.g. randomization to clinical trial)  (2) a time scale (e.g. real time (days, months, years)  (3) defnition of the event (e.g. death, relapse) 13
  • 12. Event Test Non-Event Sample of Target Randomize Population Event Control Non-Event Time to Event 14
  • 14. Why Regression for Survival Data?  Survival, in the form of hazard function, and one or more explanatory co-variables can be very interesting research investigation  The relation with risk factors can be studied using group- specific Kaplan-Meier estimates, together with Logrank and/or Wilcoxon tests  Investigating the relation with covariates, requires a regression-type model  Relating the outcome to several factors and/or covariates simultaneously requires multiple regression, ANOVA, or ANCOVA models  The most frequently used model is the Cox (proportional hazards) model 16
  • 15. Understanding the Effect of Co-variables 17
  • 16. Cox Proportional Hazards Regression  Most common Cox are linear-like models for the log hazard  For example, a parametric regression model based on the exponential distribution: loge hi(t) = α + β1xi1 + β2xi2 + … + βkxik  or, equivalently, hi(t) = exp (α + β1xi1 + β2xi2 + … + βkxik) = eα x eβ1xi1 x eβ2xi2 x … x eβkxik  Where  i indexes subjects and  xi1, xi2, …, xik are the values of the co-variates for the ith 18 subject
  • 17. Cox Model contd..  This is therefore a linear model for the log-hazard or a multiplicative model for the hazard itself  The model is parametric because, once the regression parameters α, β1, … βk are specified, the hazard function hi(t) is fully characterized by the model  The regression constant α represents a kind of baseline hazard, since loge hi(t) = α, or equivalently, hi(t) = eα, when all of the x’s are 0  Other parametric hazard regression models are based on other distributions commonly used in modeling survival data, such as the Gompertz and Weibull distributions.  Parametric hazard models can be estimated with standards softwares 19 Source: John Fox
  • 18. Cox Regression is a Proportional Hazards Model  Consider two observations, h1(t): hazard for the experimental group and h0(t): hazard for the control group h1(t)/h0(t) = exp(β)  exp (β) indicates how large (small) is the hazard in experimental group with the respect to the hazard in the reference group  and it is constant, does not depend on time. Hence, it is called “proportional hazards” over time  Other qualities:  Usually provides better estimates of survival probabilities and cumulative hazard than those provided by the Kaplan-Meier function when assumptions are met  The coefficients in a Cox regression relate to hazard  a positive coefficient indicates a worse prognosis  a negative coefficient indicates a protective effect of the variable with which it is associated 20
  • 19. Exploring Co-variables by Cox Regression 21 Source: Yesilda Balavarca, Internet
  • 20. Interpretation of Results h1 (t,X) = h0(t) exp (β1 gender + β2 treatment)  Gender: 1 = male, 0 = female; treament: 1 = experimental, 0 = control h1 (t,X) = h0(t) exp (−0.51 gender + 0.69 treatment) and exp(β1 ) = exp(−0.51 ) = 0.6 and exp(β2 ) = exp(0.69 ) = 2.0  This means a reduction of hazards for males, i.e., males have larger probabilities of survival than females  The experimental treatment increases hazard, i.e., patients receiving the new experimental treatment have lower survival probabilities than patients on the control (standard) treatment 22
  • 21. Checking Proportionality of Hazards  Check to see if the estimated survival curves cross  If they do, then this is evidence that the hazards are not proportional  More formal test: e.g., scaled Schoenfeld Residuals show interactions between covariates and time  Testing the time dependent covariates is equivalent to testing for a non-zero slope in a generalized linear regression of the scaled Schoenfeld residuals on functions of time  A non-zero slope is an indication of a violation of the proportional hazard assumption. 23
  • 22. Proportionality of Hazards: Schoenfeld Residuals 24
  • 23. Cox Regression is a Proportional Hazards Model  Cox regression (or proportional hazards regression) is method for investigating the effect of several variables upon the time a specified event takes to happen  When an outcome is death this is known as Cox regression for survival analysis  Assumptions:  the effects of the predictor variables upon survival are constant over time  are additive in one scale  Usually provides better estimates of survival probabilities and cumulative hazard than those provided by the Kaplan-Meier function when assumptions are met  The coefficients in a Cox regression relate to hazard  a positive coefficient indicates a worse prognosis  a negative coefficient indicates a protective effect of the variable with which it is associated 25
  • 24. Remember the Survival Data in Part 1? 26
  • 25. Organized Input Data Group Surv Time Surv Censor Surv Group Surv Time Surv Censor Surv 2 142 1 2 232 1 1 143 1 2 232 1 2 157 1 2 232 1 2 163 1 2 233 1 1 165 1 2 233 1 1 188 1 2 233 1 1 188 1 2 233 1 1 235 1 1 190 1 2 239 1 1 192 1 2 240 1 2 198 1 1 244 0 2 204 0 1 246 1 2 205 1 2 261 1 1 206 1 1 265 1 1 208 1 2 280 1 1 212 1 2 280 1 1 216 0 2 295 1 1 216 1 2 295 1 1 220 1 1 303 1 1 227 1 2 323 1 1 230 1 2 344 0 27
  • 28. Cox Hazard Analysis 95% Conf. Hazard = Coefficient (±) Std.Error P Exp(Coef.) Group Surv -0.5861172 0.6726008 0.343165 0.0876 0.55648 The significance test for the coefficient b1 tests the null hypothesis that it equals zero and thus that its exponent equals one The confidence interval for b1 is therefore the confidence interval for the relative death rate or hazard ratio What is your conclusion of this analysis? 30
  • 29. And the Case Study Data in Part 1? 31
  • 30. Case Study: Results  Cox proportional hazards:  Factors associated with increased mortality risk were male sex, poor KPS (< 80), presence of liver metastases, high serum lactate dehydrogenase, and low serum albumin.  Adjusted for these variables, there was no statistically significant difference in survival rates between patients treated with gemcitabine and marimastat 25 mg, but patients receiving either marimastat 10 or 5 mg were found to have a significantly worse survival rate than those receiving gemcitabine 32
  • 31. 33
  • 32. Bad or Wrong Methods of Analysis  Comparison of life tables at one point in time ignoring their structure elsewhere (except very rapid processes)  If a few patients are at risk for more than a certain time but do not die, this should not be taken as evidence of cure. Look at all the data of all the patients  Median survival times are not very reliable unless the death rate around that median is very high  A simple count of number of death in each group is inefficient as it ignores the rate of death  The best estimate of the probability of survival for a certain time (say 5 years), is given by the life table value at that time. Other simplistic calculations may be misleading  Randomized controls are always better than historical controls 34
  • 33. Bad or Wrong Methods of Analysis contd.  Estimation of survival is best done from randomization time. If it is done from the time of 1st treatment it can be misleading (as initiating time for two treatments can be different)  Superficial comparison of the slopes of survival graphs as it biases the proportion surviving at each given time  Declaring ITT is better than per protocol analysis or the reverse  Check all the data carefully especially the P values associated with either type of analysis  When you get an overall non-significant treatment effect, do not insist that a sub-stratum can still benefit from the treatment even if that stratum analysis is significant  Realistically not checking the actual number of survivors on the last day of the study (follow up)  Be sure of your reason to use and report one-sided vs. two-sided t-tests 35
  • 34. Overall Conclusions  Survival time is measured for each patient from his/her date of randomization  The life table is a table or graph estimating the proportion of surviving patients at different times after randomization  The Log Rank test is a comparison of observed and expected death in each experimental group  P value of Log Rank can be estimated by a chi square (χ2 ) test.  A patients are divided into strata (prospectively or retrospectively), K-M life tables or Log Rank can be used to compare prognosis in each stratum, for testing heterogeneity, etc.  Usually Cox regression yields slightly better analysis of cancer trial data provided assumptions are met 36
  • 37. End of Part 2 Your ?s 39
  • 38. Thank You Very Much 40